Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

CEL-SCI Corp (CVM)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow CEL-SCI's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.652 -0.068    -3.97%
17:30:49 - Real-time Cboe. Currency in USD ( Disclaimer )
  • Volume: 151,651
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.610 - 1.735
Type:  Equity
Market:  United States
CEL-SCI 1.652 -0.068 -3.97%

CEL-SCI Company Profile

 
Read the Cel-Sci company profile to learn more about the business and the management team. View CEL-SCI Corp facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

44

Equity Type

ORD

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company’s product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Contact Information

Address 8229 Boone Boulevard Suite 802
Vienna, 22182
United States
Phone 703 506 9460
Fax -

Top Executives

Name Age Since Title
Bruno Jean-Marie Baillavoine 72 2015 Independent Director
Geert R. Kersten 65 1988 Chief Executive & Financial Officer, Treasurer and Director
Mario Gobbo 71 2024 Director
Robert E. Watson 67 2017 Independent Chairman of the Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CVM Price Commentary

Write your thoughts about CEL-SCI Corp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Salva Espinosa
Salva Espinosa Aug 04, 2021 8:36
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It looks that has staiblized in this area around 8$, I think it is a really good entry point for a short a long term. With any news on their researches it could go up
Tony Lamote
Tony Lamote Mar 09, 2020 20:36
Saved. See Saved Items.
This comment has already been saved in your Saved Items
You can read my story about cel-sci $CVM https://www.scribd.com/document/450905762/CEL-SCI-True-Story-Part-1
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email